Islet Transplantation Using Campath-1H and Infliximab Induction
|Type 1 Diabetes||Drug: alemtuzumab Procedure: islet transplant Drug: infliximab||Phase 2|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Islet Transplantation in Type 1 Diabetic Patients Using Campath-1H and Infliximab Induction|
This is a single-centre, prospective, open-label study in Type 1 diabetic participants receiving an islet cell transplant; all participants will receive Campath-1H + Infliximab induction therapy followed by sirolimus and ultra-low dose tacrolimus maintenance therapy.
The primary objective of this protocol is to assess the safety of this treatment regimen in adult Type 1 diabetic participants receiving their first islet transplant.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00175266
|University of Alberta - Clinical Islet Transplant Program|
|Edmonton, Alberta, Canada, T6G2C8|
|Principal Investigator:||A.M. James Shapiro, MD, PhD||University of Alberta|